Marc Princen, Executive Vice President and President Allergan International, explains how Allergan’s novel ethos and innovative approach makes it stand out from the crowd…
Potential partners for Allergan should take note of this brave message from its Executive Vice President and President Allergan International Marc Princen: “We’re willing to take risk, we’re willing to stick our necks out and we’re willing to do what’s best for patients.”
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Allergan’s “bold” approach has put it at the forefront of both the social contract recently composed with US authorities and the ‘Open Science’ model, as well as contributing to “a pivotal year” for its business. This approach is reflected in its corporate moto: ‘Live bold and do what’s right’.
[insert_php] if ( zmember_valid_subscription() ) { echo ‘
DOWNLOAD THE ENTIRE 21st ANNIVERSARY SUPPLEMENT NOW
Our 21 @ 21 Anniversary Supplement is just one of the many resources a free subscription to European Pharmaceutical Review provides. If you are already a subscriber, login to download the PDF.
Not yet a subscriber? Join our growing community of thousands of industry professionals and gain access to:
Bi-monthly issues in print and/or digital format
Case studies, whitepapers, webinars and industry-leading content
Breaking news and features
Our extensive online archive of over 8,500 articles and past issues
As a leader in medical aesthetics, Allergan spends much of its time and resource on developing medical education so that clinicians understand how to inject its products for the best possible outcome. “We take this as our highest command that we provide not only good products, but we offer injectors the best training programmes possible,” says Mr Princen. “This is important to protect patients and to safeguard the professionals.”
Allergan is slightly different to some other pharma companies because 35% of its business is in medical aesthetics, which is a ‘cash pay’ business funded by private rather than public money. This makes funding “a personal choice,” says Mr Princen.
Most of Allergan’s European business is in eyecare, while in the US it is in GI and CNS. The company has delivered a good performance this year, based on a 9% topline growth in its YTD quarter two results and meeting earning-per-share growth expectations. “We’ve just reconfirmed our expectations for the end of the year and confident that we’re on the right track to meet that.” Allergan launched 11 new products in 2016/17 and completed 14 major pharma and device submissions.
Allergan is at the forefront of Open Science, a model now being considered by several other manufacturers. Partnerships with other drug developers mean that, rather than carrying out the whole cycle of drug development, it can take on interesting compounds, carry out the phase 2 and 3 clinical trials, and take the medicine to the global market.
Speed to market is a significant advantage of the Open Science model. And Allergan can bring new medicines to market relatively quickly because it does not have a huge internal R&D section to filter its projects through. “We’re pretty clean and that’s an advantage.”
The social contract
Allergan’s Chief Executive Brenton Saunders has been at the forefront of the social contract recently composed with US authorities, which promises no price hikes, price increases limited to once a year, and single digit increases. This reflects Allergan’s desire to be “as reasonable as possible” about price increases, says Mr Princen. Outside of the US, Allergan works closely with the relevant reimbursement and payor groups Marc Princen, Executive Vice President and President Allergan International to establish appropriate value for medicines. “We want to bring the right medicine at an affordable price to patients.”
The social contract takes a holistic view of medicines manufacture and delivery and has four principles:
Invest and innovate
Access and pricing
Quality and safety
Education.
Mr Saunders has warned that the fragile innovation ecosystem has come under assault from price rises and could quickly fall apart if it is not continually nourished with the confidence that there will be a longer term opportunity for appropriate return on investment. He has committed to living by the four principles of the social contract and urged his Allergan colleagues to keep this social contract in mind as they make business decisions that ultimately improve wellbeing.
Taking forward lessons from the past
Mr Princen believes that one of the most significant developments in pharma over the past 15-18 years has been the increased importance of stakeholders and payers and governments into the total business and the weight they have gained versus the normal prescribers of innovative drugs. Another significant development has been the advent of gene therapy and how it will allow personalised medicines going forward. This will make the payor landscape even more important, as these types of treatment can costs hundreds of thousands of dollars per patient. “The payor landscape going forward will become even more distorted than before and we will have to look for solutions to ensure these innovative therapies are utilised.”
For the future, Mr Princen predicts that innovative medicine and gene therapy will change the course of certain diseases and that the funding of these treatments will become an issue for governments worldwide. “This is going to be a challenge for the whole industry. How are we going to fund that innovation going forward? A lot of creative thinking is needed in terms of what type of patent schemes and risk-sharing models can be developed.”
The likes of Novartis and Gilead, which are bringing innovative treatments to market, will develop novel funding models for these drugs, Mr Princen predicts. “The world will somehow adapt to this over the next three to five years.”
Meanwhile, Allergan is playing its part in taking the funding model forward. “In relation to the traditional model our company has taken the lead with not having price hikes on medicines. That shows that we’re people that want to take responsibility and try to find solutions.”
Allergan’s role in the medical aesthetics area and how its offerings will help people to age delivers “a unique prospect”, and this is one of the company’s outstanding achievements in an age when people are living 20 years longer than might be expected. “I’m very enthusiastic about the medical aesthetics space, which we’re world leaders in. We can help people to age in a very respective manner and keep up with the challenges of the future. That’s a very unique aspect of Allergen.”
Partnership working will be key to Allergan’s continued growth. “I think it will be important to do win/win type of partnerships with companies stronger in certain areas and that can add to the strength of Allergan.” And partnerships with leaders in digital technology will be particularly important to deliver products quickly and effectively to customers.
Mr Princen shares one key message with potential partners: “If you want to have a bold partner who is very assertive and very agile, we’re the best.”
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.